The anti-angiogenic medication Zaltrap/Aflibercept works by binding to vascular endothelial growth factor (VEGF) and placental growth factor (PLGF), which inhibits angiogenesis in patients with recurring glioblastoma, resulting in anti-tumor effects. Here, VEGFA is linked to neoplasm.